NewAmsterdam Pharma Co (NAMS, Financial) has caught the attention of Citigroup, as the financial giant initiates coverage on the stock with an optimistic 'Buy' rating. This move, led by analyst Geoff Meacham, highlights the firm's positive outlook on the pharmaceutical company.
Alongside the 'Buy' rating, Citigroup announced a price target for NAMS set at USD 42.00. This indicates the analyst's projection of a potential growth trajectory for NewAmsterdam Pharma Co's stock value.
Given that this is the first rating and price target assigned by Citigroup for NAMS, it marks a significant development for investors tracking the company. As of the announcement on June 17, 2025, the stock's performance will be closely watched to see how it aligns with Citigroup's forecast.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for NewAmsterdam Pharma Co NV (NAMS, Financial) is $44.00 with a high estimate of $52.00 and a low estimate of $37.00. The average target implies an upside of 122.78% from the current price of $19.75. More detailed estimate data can be found on the NewAmsterdam Pharma Co NV (NAMS) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, NewAmsterdam Pharma Co NV's (NAMS, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
